"With the purchase of this production company, we are laying an important foundation stone for our ambitious growth targets," said Managing Director and CFO Gerhard Mayer. "Together with the Polish management, we will develop the site into a center of excellence for oral dosage forms for the Wörwag Pharma group."
Wörwag Pharma is investing primarily in the expansion of its global product portfolio and the development of new markets.
With the acquisition of Sensilab, the company is securing the necessary production capacities in addition to its existing partnerships with suppliers. On the other hand, Wörwag will be able to guarantee a reliable supply chain and provide its customers with continuous access to high-quality products.
The modern building complex for production and development offers the opportunity to create capacity for further growth. The location is logistically favorable for supplying the core markets in Eastern Europe. In addition, Sensilab brings further expertise to the company to expand the product portfolio by developing its own innovations.
About Woerwag Pharma
Woerwag Pharma GmbH & Co. KG is a family-owned, pharmaceutical company headquartered in Boeblingen, Germany, developing and selling biofactor preparations wordwide. The company’s product range is exclusively available in pharmacies and includes both prescription preparations as well as over the counter (OTC) products and food supplements. Therapeutic areas focus on diabetes and associated diseases, nervous system and musculo-skeletal system.
In 2020, the company achieved a sales revenue of more than 235 million euros with 1000 employees in more than 35 countries. This year, the company celebrates its 50th anniversary.
About Sensilab
Sensilab is a contract manufacturer and development service provider for tablets, powders, granules and hard capsules. The production site in Konstantynów Łódzki in the greater Lodz area, Poland, employs 180 people who supply customers mainly in the European region. Sensilab most recently belonged to the Polish USP group of companies.
Press Contact
Wörwag Pharma GmbH & Co. KG
Tanja Thoma-Ly
Corporate Communications
Phone: +49 7031 62 04-338
tanja.thoma-ly(at)woerwagpharma.com
